CADILA HEALTH CARE LTD. vs CADILA PHARMACEUTICALS LTD.

The Supreme Court ruled on the trademark dispute between two pharmaceutical companies regarding the use of the names 'Falcigo' and 'Falcitab'. The Court held that the similarity in names did not warrant an injunction as the drugs were distinct in formulation and sold exclusively to hospitals, thus minimizing the likelihood of consumer confusion. The Court referenced Sections 391 and 394 of the Companies Act concerning corporate restructuring and affirmed the lower court's dismissal of the injunction application, concluding that there was no case for confusion or deception.